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Original Article 
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ABSTRACT: Lipoprotein-associated phospholipase A2 (Lp-PLA2) and superoxide dismutase (SOD) are linked to 
regulating vascular/neuro-inflammation and stroke. Using a retrospective design, we investigated whether circulating 
Lp-PLA2 and SOD in cerebral small vessel disease (CSVD) patients  were associated with cognitive impairment. 
Eighty-seven CSVD patients were recruited. Plasma Lp-PLA2 and SOD were determined, and cognitive status was  
measured by the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA). The severity 
of white matter hypoerintensities (WMHs) in CSVD patients was rated according to Fazekas scales , and Lp-
PLA2/SOD levels and MMSE/MoCA were compared. Multiple linear regressions were used to evaluate the 
relationship between Lp-PLA2 and SOD and the cognitive impairment. Ordinal logistic regression and generalized 
linear models (OLRGLMs) were applied to confirm whether Lp-PLA2 and SOD are independent risk factors for 
cognitive impairment in CVSD. Lp-PLA2 and SOD with mild or severe cognitive impairment were lower than those 
with normal congnition. Lp-PLA2 and SOD in CSVD patients with severe WMHs were significantly lower than those 
with mild or moderate WMH lesions. We noted positive linear associations of Lp-PLA and SOD with cognitive 
impairment in CSVD, independent of LDL-C. OLRGLMs confirmed that Lp-PLA2 and SOD were independent risk 
factors of cognitive impairment in CSVD. Lp-PLA2 and SOD are independently associated with cognitive impairment 
and WMH lesion, and may be useful for the rapid evaluation of cognitive impairment in CSVD. Lp-PLA2/SOD are 
modifiable factors that may be considered as therapeutic targets for preventing cognitive impairment in CSVD.  
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Cerebral small vessel disease (CSVD) is a highly 
prevalent condition associated with neuroinflammation 
and cognitive impairment [1, 2]. However, the diagnosis  
and classification of CSVD with cognitive impairment  
were somewhat difficult for community doctors or non-
Stroke subspecialist. Clinically, there is no blood marker 
available to diagnose and assess CSVD with cognitive 
impairment in clinical settings [3, 4]. Worldwide, the 
number of CSVD patients is more common in Asians than 
in Caucasians [5]. Growing evidence has shown that 
systemic inflammatory mediators such as superoxide 
dismutase (SOD) and lipoprotein-associated phospho-
lipase A2 (Lp-PLA2) are associated with CSVD and 
cognitive impairment [4, 6-8]. However, the role of Lp-
PLA2 and SOD, especially SOD, in CSVD patients with 
cognitive impairment is largely unknown. 
Lp-PLA2 acts as an enzyme and proinflammatory 
marker of cardio- and cerebrovascular risk; however, 
some studies have indicated that Lp-PLA2 exerts 
antioxidative and anti-inflammatory functions under 
certain circumstances [9]. Lp-PLA2 circulates in plasma 
in its active form as a complex with low-density 
lipoprotein (LDL) and high-density lipoprotein (HDL).  
SOD is an enzyme that catalyzes the dismutation of the 
superoxide radical into H2O2 and oxygen and has 
powerful anti-inflammatory activity [10, 11]. A recent 
study in humans suggested that plasma SOD could be a 
marker of vascular alterations. Other studies have also 
indicated that higher levels of Lp-PLA2 are associated 
with cerebral ischemic stroke and cognitive impairment [7, 
8, 11]; however, the roles of SOD in cognitive impairment 
remain unexplored. 
To explore the association of Lp-PLA2 and SOD with 
CSVD patients with cognitive impairment, we asked 
whether (1) plasma Lp-PLA2 and SOD levels in CSVD 
patients with cognitive impairment were higher or lower 
than those in CSVD patients with normal cognition [NC], 
(2) there was a certain linear relationship between Lp-
PLA2/SOD and cognitive impairment in CSVD, and (3) 
the Lp-PLA2/SOD-related receiver operating 
characteristic (ROC) curve could be used to distinguish 
CSVD with mild or severe cognitive impairment [MCI, 
SCI] from those with NC.  
 
MATERIALS AND METHODS 
  
Study design 
 
This study was a retrospective analysis of collected data 
from patients admitted with subcortical white matter 
hyperintensity (WMH) and lacunar infarct in two medical 
centers (Zhujiang hospital and Guangzhou General 
Hospital of Military Command, Guangzhou, China). The 
study was approved by the ethics Human Research 
Committee at Zhujiang Hospital of Southern Medical 
University and complied with the principles outlined in 
the revised Declaration of Helsinki of 1975 and the 
National Institutes of Health Human Subjects Policies and 
Guidelines released in 1999. Informed written or verbal 
consent was obtained from patients and family members. 
 
 
 
Figure 1. All 120 CSVD patients who met the clinical 
diagnostic criteria of white matter hyperintensities were 
enrolled in this study from Jul 2017 to Aug 2018. Of 33 
participants met the excluded criteria and 87 participants were 
included in this study for further analyzing. 30 age and gender-
matched non-CSVD healthy controls (HC) were enrolled from 
physical examnination center. The plasma level of Lp-PLA2 and 
SOD was compared between CSVD and HC groups. In addition, 
The cognitive function and white matter hyperintensity  were 
evaluated and the variables were collected and analyzed among 
groups.  
 
 
 Patient selection 
  
One-hundred and twenty consecutive CSVD participants  
with Magnetic Resonance Imaging (MRI)-determined 
subtypes (WMH and lacunar infarcts) were recruited from 
July 2017 to August 2018. All participants were clinically 
diagnosed with CSVD at Zhujiang hospital and 
Guangzhou General Hospital of Military Command based 
on the criteria of Trial of Org 10172 in Acute Stroke 
Treatment [12]. All participants underwent T2, T1 turbo 
field echo, fluid-attenuated inversion recovery (FLAIR) 
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imaging using a 3.0-T MRI scanner (Philips 3.0T Achieva; 
Philips Healthcare, Andover, MA). Subcortical WMHs 
were defined according to the study of Mok [13]. A lacune 
was defined as a round or ovoid lesion ≥3 mm and ≤15 
mm in diameter found on T1-weighted and T2-weighted 
images with a perilesional halo on FLAIR images as 
defined by Wardlaw et al [14]. The study flow diagram 
was shown in Figure 1. Of the 120 participants, we 
excluded 18 patients who showed extra-intracranial large 
artery stenosis ≥50% and 3 who exhibited a cortical 
nonlacunar infarct. Others with subcortical nonlacunar 
infarct (n=2), cerebral hemorrhage (n=1), cardio embolic 
source infarct (n=1), Alzheimer disease (AD; n=2), 
serious psychological disease (n=2), drug and alcohol 
abuse (n=2), severe deaf (n=2), were also excluded from 
this study. Thus, the final analysis was performed in 87 
CSVD eligible participants. In addition, 30 age-and 
gender-matched healthy control (HC) subjects were 
recruited at the physical examination center and the 
plasma levels of Lp-PLA2 and SOD were collected. We 
received written informed patient consent to perform this 
study.  
 
Participant characteristics 
 
Eligible participant characteristics that were regarded as 
likely relevant confounders of cognition or Lp-PLA2 
were recorded as baseline data. In this study, the following 
variables were collected: 1) demographic data (gender, 
age, years of education); 2) clinical data (body mass index 
[BMI], history of hypertension, diabetes and coronary 
heart disease [CHD], medical history of statin and 
antithrombotic use), with hypertension and diabetes  
mellitus defined as a self-reported medical diagnosis,  
antihypertensive/antidiabetic medication use, or a new 
diagnosis according to increased fasting and postprandial 
blood glucose, or CHD defined as a self-reported medical 
diagnosis or heart disease medication use, and BMI 
calculated as weight divided by height squared (kg/m2); 3) 
laboratory markers such as cholesterol metabolism-
relevant biomarkers including LDL-cholesterol (LDL-C), 
HDL-cholesterol (HDL-C) and total cholesterol, kidney 
function-relevant biomarkers including urea, creatinine 
(Cr) and UA, and ROS markers including Lp-PLA2 and 
SOD; 4) genetic data such as apolipoprotein E (APOE)  
allele carrier status. 
    
Cognitive impairment severity grading  
 
The diagnosis of cognitive impairment was performed by 
two neruologists according to the criteria proposed by 
Philip B., which was recommeded by Guidelines for 
Cerebral Vascular Diseases[15]. Cognitive domains  
including executive/attention, memory, language, and 
visuospatial functions were assessed. A decline in 
cognitive function from a prior baseline in at least one 
cognitive domain and normal or mildly impaired 
instrumental activities of daily living were defined as MCI.  
A deficit in performance in ≥2 cognitive domains that are 
of sufficient severity to affect the subject’s activities of 
daily living was defined as SCI. The Mini-Mental State 
Examination (MMSE) and Montreal Cognitive 
Assessment (MoCA) were evaluated on the day of 
administration.  
 
Laboratory biomarker measurements 
 
Total cholesterol, HDL-C, LDL-C, urea, leukocyte, 
neutrophile granulocyte (NEU), hypersensitive C-reactive 
protein (hs-CRP), erythrocyte sedimentation rate (ESR), 
Cr, UA, Lp-PLA2, APOE and SOD in the plasma were 
measured twice during hospitalization. Fasting blood 
samples were collected in tubes containing EDTA and 
centrifuged at 3000 g for 10 min, and aliquots of plasma 
were stored at -70°C until use for biochemical analyses. 
Since the Lp-PLA2 mass test only detects a portion of the 
total Lp-PLA2, mainly the Lp-PLA2 associated with 
HDL, which is the “good cholesterol” that displays  
protective effects [16], and we wanted to explore the 
neuroprotective effects of plasma Lp-PLA2, therefore 
here we only measured Lp-PLA2 mass in the current study. 
Lp-PLA2 mass was detected with the Human 
PLA2G7/PAF-AH/Lp-PLA2 Quantikine Enzyme-linked 
Immunosorbent Assay (ELISA) Kit (Bio-Techne 
Corporation, R&D system, Minnesota) according to the 
referenced instructions by Packard et al. and the 
manufacturer’s instructions [17]. Briefly, 10 µL EDTA 
plasma was added to a 96-well plate precoated with an 
antibody specific to Lp-PLA2. After incubation with the 
Lp-PLA2-specific primary and biotin-conjugated anti-
bodies, the plasma concentration of Lp-PLA2 was 
determined by comparing the optical density (O.D.) of the 
samples to the standard curve. Plasma SOD levels were 
measured with a Cu/Zn SOD ELISA kit (Bio-Techne 
Corporation, R&D system, Minnesota, USA) according to 
the manufacturer’s instructions. Absorbance was read on 
a spectrophotometer (Thermo Luminoskan Ascent, 
Waltham MA, USA) at 450 nm [10]. 
  APOE genotyping was detected by Q-PCR as 
described by Christensen et al., [18]. Genomic DNA was 
extracted from blood samples using Qiagen DNA Blood 
kits (#51162; Qiagen Inc., Valencia, CA, USA). SNP-
specific primers and probes were designed by Invitrogen 
(Invitrogen,). TaqMan real-time PCR assays were 
performed in an ABI 7900 HT machine, using the 
following cycling program: 95°C for 10 min followed by 
40 cycles of 95°C for 15 sec and 60°C for 1 min.    
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Figure 2. Comparison of biomarkers for Lp-PLA2 and SOD levels in the CSVD patients with different 
severity of cognitive impairment. (A) Comparison was made using independent t-test between the CSVD patients 
and HC (healthy control). The level of Lp-PLA2 increased and SOD decreased in CSVD patients. (B) Comparisons 
were made using one-way covariance with adjusted for the confounders (sex, age, education, BMI, cholesterol, 
HDL-C, LDL-C, urea, Cr, UA, hypertension, diabetes, CHD, APOE genotype, and medication use) followed by a 
post hoc Bonferroni test. Cognitive impairment group (MCI and SCI) displayed significantly lower levels of Lp -
PLA2 and SOD than the normal cognition (NC) group (see also table 1). (C) The plasma Lp-PLA2 was linear 
correlated with SOD (r=0.327, p <0.05). Abbreviations: APOE, apolipoprotein E; BMI, body mass index; CHD, 
coronary heart disease; Cr, creatinine; CSVD, cerebral small vessel disease; HC, healthy control; HDL-C, High-
density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Lp-PLA2, Lipoprotein-associated 
Phospholipase A2; MCI: mild cognitive impairment; MMSE, Mini-Mental State Examination; MoCA, Montreal 
Cognitive Assessment; NC, normal cognition; SCI, severe cognitive impairment; SOD, Superoxide Dismutase; UA, 
uric acid. * Compared to NC p <0.05, ** Compared to NC p <0.01, *** Compared to NC p <0.001, ## Compared 
to MCI p <0.01.  
The rating of white matter hyperintensities with Fazekas 
scales  
 
MRI including T2 and FLAIR sequences were used in this 
study. The severity of white matter hypoerintensities 
(WMHs) was rated according to Fazekas scales by two 
raters. [19] According to the scores of Fazekas, the CSVD 
patients were divided into three groups (1: Mild WMHs, 
2: Modest WMHs, 3, Severe WMHs).   
 
Statistical Analysis  
 
All data analyses were conducted using SPSS 20.0 (IBM 
Corporation, Armonk, NY, USA). A *p-value ＜0.05 was 
considered significant. All continuous variables, for 
example age, BMI, MoCA score, MMSE score, and Lp-
PLA2, SOD, UA and lipid concentrations, are shown as 
the mean ± SD; all categorical variables, such as gender, 
APOE genotype, hypertension, and diabetes, are 
presented as a percentage. Significant differences in Lp-
PLA2 and SOD between healthy and CSVD subjects were 
analyzed with independent t-test; while differences in 
plasma Lp-PLA2 and SOD levels among CSVD patients  
with different degrees of cognitive impairment, and 
differences in Lp-PLA2 and SOD levels among CSVD 
patients with different degrees of WMHs were analyzed 
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with one-way covariance followed by a post hoc 
Bonferroni test. Pearson correlation analysis was used to 
examine the relationship between Lp-PLA2 and other risk 
factors. Multiple linear regressions with a backward 
elimination model were used to detect the adjusted partial 
linear correlation between Lp-PLA2/SOD and 
MMSE/MoCA scores. Ordinal logistic regression and 
generalized linear models (OLRGLMs) were used to 
detect the significantly independent associated factors for 
cognitive decline in CSVD. To assess the diagnostic value 
of Lp-PLA2 and SOD in the identification of CSVD with 
MCI or SCI and discrimination from CSVD with NC, 
ROC analysis was conducted, and the ROC curve for the 
combination of Lp-PLA2 and SOD was calculated to 
screen for a better diagnosis tool. 
 
Table 1. Baseline Characteristic of Study CSVD Population. 
 
Variable 
Subgroup comparison 
NC (N= 46) MCI (N=30) SCI (N=11) F or X
2
 * p value 
Demographic 
     
Age, mean (SD), y 63.9(10.1) 67.9 (12.1) 74.2(13.7) 4.039 .021
#
 
Male, N (%) 29 (63.4) 19 (63.3) 8 (72.7) 0.384 .902 
Education, mean (SD), y 9.0 (3.4) 7.5 (2.1) 6.6 (2.7) 4.243 .018
##
 
Clinical      
BMI, mean (SD) 23.9(2.8) 23.1(3.2) 24.0(4.5) 0.600 .551 
Hypertension, N (%) 28 (60.9) 16 (53.3) 9 (81.80) 2.743 .274 
Diabetes, N (%) 13(28.3) 7(23.3) 4(36.4) 0.706 .706 
CHD, N (%) 20 (43.5) 11(36.7) 7 (63.6) 2.381 .301 
Statin Use, N (%) 43 (93.5) 24 (80.0) 9 (81.8) 3.336 .165 
Antithrombotic use, N (%) 44 (95.7) 24 (80.0) 9 (81.8) 4.926 0.072 
Laboratory mean (SD)      
Cholesterol, (mmol/L) 4.8±1.0 4.4±1.0 4.1±1.1 2.874 .062 
HDL-C, (mmol/L) 1.3±0.5 1.2±0.4 1.2±0.2 0.621 .540 
LDL-C, (mmol/L) 2.7±0.9 2.6±0.7 2.5±0.9 0.561 .573 
Urea, (mmol/L) 5.3±1.4 6.0±1.5 6.0±2.9 1.909 .155 
Cr, (umol/L) 78.6±28.1 84.2±34.1 97.7±36.5 1.690 .191 
UA, (umol/L) 408.8±115.0 384.3±110.2 386.3±122.2 0.478 .622 
Leukocyte, (G/L) 6.8±1.8 7.6±2.4 7.0±1.5 1.456 0.239 
NEU, (G/L) 4.2±1.4 4.9±2.2 4.8±1.4 1.702 0.189 
NEU  60.8±9.0 62.7±9.9 67.3±7.3 2.256 0.111 
Hs-CRP, (mg/L) 3.4±4.1 4.4±10.2 3.0±2.0 0.143 0.867 
ESR, (mm/H) 22.4±17.0 30.2±28.7 23.6±18.3 0.752 0.476 
Lp-PLA2 mass, (mg/L) 246.2 ±45.4 212.4±35.3 189.2±30.7 11.82 <0.001*** 
SOD, (KU/L) 149.6±24.3 135.4±16.4 120.7± 12.3 10.354 <0.001*** 
Genetic      
APOE4 carrier, No. (%) 6 (13.0) 3(10.0) 1(9.1) 0.237 .897 
 
Data shown are mean ± S.D. The comparisons of Lp-PLA2 and SOD among the groups were done with one-way covariance with adjusted 
for the confounders (see also Fig. 3). Comparisons of confounders were made using one-way ANOVA followed by Bonferroni post-hoc 
tests. Values with p<0.05 was regarded as significant related to multiple comparisons. Abbreviations: NC, normal cognition; MCI: mild 
cognitive impairment; SCI, severe cognitive impairment; MMSE, Mini-Mental State Examination (range, 0-30, with 30 a perfect score); 
BMI, body mass index; CHD, coronary heart disease; HDL-C, High-density lipoprotein cholesterol; LDL-C, low-density lipoprotein 
cholesterol; Cr, creatinine ; UA, uric acid; Che, Cholinesterase; APOE, apolipoprotein E. Lp-PLA2, Lipoprotein-associated 
Phospholipase A2; SOD, Superoxide Dismut ase; NEU, Neutrophile granulocyte; hs-CRP, hypersensitive C-reactive protein; ESR, 
Erythrocyte sedimentation rate. 
#
 Compared to NC p = 0.023, ## Compared to NC p=0.05 
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RESULTS   
 
Participant characteristics   
 
Eighty-seven participants were successfully screened and 
enrolled in the study, and neuropsychological test (MMSE 
and MoCA) evaluations were acquired for each 
participant. Forty-six of the patients with CSVD had NC 
(MMSE score exceeded 24 points), whereas 30 of the 
CSVD patients were classified as having MCI (MMSE 
score ranged from 18 to 23) and 11 participants as having 
SCI with an MMSE score no more than 17 points. Patients 
characteristics, including sex, age, BMI, past medical 
history (hypertension, diabetes and heart disease), plasma 
biomarkers, medication history (antithrombotic, lipid -
regulating drugs), biomarkers of systemic inflammation 
(leukocyte, hs-CRP, neutrophile granulocyte, ESR) and 
APOE genotype, were summarized and included in this 
study (Table 1). Interestingly, besides significant 
differences were found among the groups in age (F=4.039, 
p=0.021) and years of education (F=4.243, p=0.018), we 
noted signifcant differences of Lp-LPA2 (F=11.82, 
p<0.001) and SOD (F=10.354, p<0.001) among NC, MCI 
and SCI groups. However, no significant differences in 
BMI, cholesterol, HDL-C, LDL-C, leukocyte, hs-CRP, 
neutrophile granulocyte, ESR, Urea, Cr, UA, sex, 
hypertension, diabetes, CHD, APOE genotype, or 
medication use among three groups were observed in this 
study.  
 
Comparison of plasma Lp-PLA2 and SOD levels in 
CSVD patients 
    
Plasma Lp-PLA2 and SOD levels in CSVD patients  
across all groups were higher than those in HC (Fig. 2A). 
Analysis of covariance showed significant differences in 
Lp-PLA2 and SOD levels among the CSVD groups (SCI, 
MCI and NC) after adjusting other confounders for sex, 
age, education, BMI, cholesterol, HDL-C, LDL-C, urea, 
Cr, UA, hypertension, diabetes, CHD, APOE genotype, 
and medication use (F=11.82, p<0.001 for Lp-LPA2; 
F=10.354, p<0.001 for SOD, Table 1). Bonferroni post 
hoc comparisons showed that there were significant 
differences in Lp-PLA2 and SOD levels between the NC 
and MCI (p=0.002 for Lp-PLA2; p=0.013 for SOD) and 
between the NC and SCI groups (p<0.001 for Lp-PLA2; 
p p<0.001 for SOD, Fig. 2B). To evaluate whether there 
was a relationship between Lp-PLA2 and SOD levels, 
Pearson’s correlation between plasma Lp-PLA2 and SOD 
levels was analyzed. Lp-PLA2 levels were positively 
correlated with SOD levels (r=0.327, p<0.001), showing 
a linear relationship (Fig. 2C).    
 
 
Table 2.   Ordinal logistic regression of possible variables 
associated with cognitive decline in CSVD. 
 
Variable 
O R 
Adjusted OR 
(95% CI) 
p value 
Age (years) 1.050 (0.991-1.120) 0.097 
BMI 0.887 (0.715-1.100) 0.275 
Education (years) 0.693 (0.528-0.908) 0.008** 
Hypertension 0.652(0.154-2.759) 0.561 
Diabetes, n (%) 2.176(0.450-10.525) 0.334 
CHD, n (%)  2.236(0.522-9.528) 0.278 
Cholesterol (mmol/L) 0.562(0.265-1.195) 0.134 
HDL cholesterol (mmol/L) 0.966 (0.182-5.109) 0.080 
LDL cholesterol (mmol/L) 2.601(0.942-7.184) 0.065 
Urea (mmol/L) 1.521(1.015-2.280) 0.042 
Cr (umol/L) 1.002(0.981-1.024) 0.848 
UA (umol/L) 1.002(0.996-1.008) 0.466 
SOD (KU/L) 0.933 (0.895-0.972) 0.001** 
Lp-PLA2 mass (mg/L) 0.977 (0.962-0.992) 0.003** 
Antithrombotic use, n (%) 8.069(0.327-199.032) 0.202 
Statin use, n (%) 0.871(0.048-15.196) 0.925 
 
Lower levels of education (p=0.008), relatively lower levels of SOD 
(p=0.001) and Lp-PLA2 (p=0.003) were independent associated factors 
of cognitive decline in patients with CSVD.  
 
Comparison of plasma levels of Lp-PLA2 and SOD in 
CSVD with different severity of WMHs 
 
Both MMSE (F=5.582, p<0.01) and MoCA (F=3.488, 
p<0.05) scores significantly decreased in severe WMHs 
patients as showed in Figure 3D and E. According to the 
scores of Fazekas, the CSVD patients were divided into 
three groups as classified by the severity of WMH (1: 
Mild WMHs, 2: Modest WMHs, 3, Severe WMHs),  
which was shown in Figure 3A. The relatively lower 
levels of Lp-PLA2 (F=6.522, p<0.01) and SOD (F=3.396, 
p<0.05) were observed in severe WMHs subjects 
compared to those in the mild group (Fig. 3B, C).  
 
Linear correlation between plasma Lp-PLA2/SOD levels 
and MMSE or MoCA scores 
   
The results from the backward elimination for multiple 
linear regression with adjustment for LDL-C and other 
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parameters including age, gender, degree of education, 
hypertension, diabetes mellitus, CHD, statin use, 
antithrombotic use, HDL-C, cholesterol, urea, and Cr are 
presented in Supplementary Table 1 and Figure 4. The 
correlations between Lp-PLA2 and MMSE, and between 
SOD and MMSE were analyzed (Pearson correlation 
coefficient: 0.438 and 0.397, respectively, Fig. 4A, C). 
Linear regression analysis (Fig. 4A, C) showed that there 
was a linear relationship between Lp-PLA2 and MMSE,  
with linear regression equation Y=12.182+0.046*X, and 
between SOD and MMSE, with linear regression equation 
Y=11.093+0.081*X. Furthermore, another cognition 
evaluation tools, MoCA was also applied in this study to 
confirm the relationship between Lp-PLA2/SOD, and 
results showed that a linear relationship was also found 
between Lp-PLA2/SOD and MoCA scores. The linear  
regression equation was Y=6.780+0.049*X between Lp-
PLA2 and MoCA, and Y=2.103+0.111*X between SOD 
and MoCA scores (Fig. 4B, D).  
 
 
Figure 3. Comparison of Lp-PLA2 and SOD in the CSVD patients with different severity 
of WMHs. (A) The representative MRI imagings of WMHs in CSVD patients with different 
severity classified by Fazekas Scores. The levels of Lp-PLA2 (B) and SOD (C) were relatively 
lower in the CSVD patients of Severe-W compared to those in the Mild-W. The scores of MMSE 
(D) and MoCA (E) were lower in patients in the Severe-W group compared to those in the Mild-
W group. Abbreviations: CSVD, cerebral small vessel diseases; MMSE, Mini-Mental State 
Examination; Mild-W, Mild-White matter hyperintensities, MoCA, Montreal Cognitive 
Assessment; Modest-W, Modest- White matter hyperintensities, MRI, Magnetic Resonance 
Imaging; Severe-W, Severe-White matter hyperintensities, SOD, Superoxide Dismutase; 
WMHs, White matter hyperintensities. * Compared to Mild-W p <0.05, ** Compared to Mild-
W p <0.01. 
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Figure 4. Linear correlation of plasma Lp-PLA2 and SOD with MMSE or MoCA. (A) Lp-PLA2 level in plasma samples 
were measured. After adjusting for confounders, Lp-PLA2 linear correlated with cognitive impairment severity as measured by 
MMSE scores (r=0.438, p <0.001). (B) A similar trend was observed between SOD and MMSE score, and the correlation was 
statistically significant (r=0.379, p <0.01). (C) After adjusting for confounders, Lp-PLA2 linear correlated with cognitive 
impairment severity as measured by MoCA scores (r=0.397, p <0.001). (D) A similar trend was observed between SOD and 
MoCA score, and the correlation was statistically signficant (r=0.443, p<0.001). Abbreviations: Lp-PLA2, Lipoprotein-associated 
Phospholipase A2; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; SOD, Superoxide 
Dismutase.  
Lp-PLA2 and SOD as independent factors to predict CI 
in CSVD 
 
Ordinal logistic regression and generalized linear models  
were used to examine the association between the two 
biomarkers and the extent of cognitive impairment. The 
results showed that relatively low levels of Lp-PLA2 (OR 
0.977, p=0.003) and SOD (OR 0.933, p=0.001) were 
significant independent risk factors for cognitive 
impairment in CSVD patients as shown in Table 2. The 
predictive value of other variables, such as education and 
urea are also shown in Table 2. 
 
ROC analysis of the utility of Lp-PLA2 and SOD levels 
in the diagnosis of CSVD with CI 
 
Due to the interaction between Lp-PLA2 and SOD, the 
ability of the combination of these two variables to serve 
as a better diagnostic value was examined. ROC curves 
were constructed, and the areas under the curves (AUCs) 
were calculated to assess the value and accuracy of Lp-
PLA2 and SOD for discriminating CSVD patients with 
MCI from those CSVD patients with NC. The AUCs for 
Lp-PLA2 and SOD to discriminate between NC and MCI 
were 0.737 and 0.670, respectively; however, the 
combination of Lp-PLA2 and SOD increased the AUC to 
0.770. The Youden index was 1.5087 for Lp-PLA2,  
1.3783 for SOD, and 1.4957 for their combination (Fig. 
5). The value of Lp-PLA2 and SOD for discriminating 
CSVD patients with SCI from those CSVD patients with 
NC was also evaluated. The AUCs for Lp-PLA2, SOD, 
and their combination to discriminate between NC and 
SCI were 0.855, 0.841. 0.899, respectively, while the 
Youden indices were 1.6483, 1.6739, and 1.7134. The 
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sensitivity and specificity for Lp-PLA2 alone was 90.91% 
and 73.92%, respectively; however, combined with SOD, 
the specificity increased to 80.43% (Fig. 5).   
 
 
 
 
Figure 5. ROC analysis of Lp-PLA2 and SOD. (A) Lp-PLA2 and SOD for CSVD patients with MCI versus CSVD patients 
with NC. The combined graph showed the Lp-PLA2 (black curve), SOD (red curve) and the combination curve (green curve) 
respectively. The combination of Lp-PLA2 and SOD was the best discriminating parameters compared to Lp -PLA2 and SOD 
alone. (B) ROC analysis of Lp-PLA2 and SOD for CSVD patients with SCI versus NC. The AUC was 0.85 for Lp-PLA2 (black 
curve), 0.84 for SOD (red curve) and 0.90 for the combination of Lp-PLA2 and SOD (green curve). Abbreviations: CSVD, Lp-
PLA2, Lipoprotein-associated Phospholipase A2; SOD, Superoxide Dismutase; MCI, Mild Cognitive Impairment; SCI, severe 
cognitive impairment. 
 
DISCUSSION  
 
Inflammation plays a crucial role in the pathogenesis of 
cerebral ischemia including CVSD and dementia such as 
AD and MCI [2, 20, 21]. Plasma levels of vascular and 
neuroinflammation-related markers including Lp-PLA2 
and SOD have been used as specific measures of 
cerebrovascular inflammation in ischemic stroke. 
Although the role of lipoprotein-associated phospholipase 
A2 in cognitive impairment is known; however, the role 
of SOD in cognitive impairment especially in CSVD 
patients remains largely unexplored. In this study, for the 
first time to our knowledge, we found the relation of Lp-
PLA2 and SOD with cognitive impairment in CSVD 
patients. Our findings provide several novel observations. 
First, we note that plasma Lp-PLA2 and SOD levels in 
CSVD patients with MCI or SCI were lower than those in 
CSVD patients with NC and that the two markers were 
positively correlated to the degree of cognitive 
impairment in CSVD patients. Second, our study 
suggested that Lp-PLA2 and SOD may be closely 
correlated to the severity of white matter lesion in CSVD 
patients. Third, multiple linear regression showed a 
significant association between Lp-PLA2/SOD and the 
degree of cognitive impairment as measured by the 
MMSE and MoCA scores in CSVD patients, independent 
of LDL-C. Fourth, we further confirmed that Lp-PLA2 
and SOD were significant independent risk factors for 
cognitive impairment in CSVD patients as examined by 
OLRGLMs. Finally, this study created Lp-PLA2 and 
SOD-related ROC curves to distinguish CSVD patients  
with MCI from those with NC. Together, these data 
support the integral roles of the vascular and 
neuroinflammatory markers Lp-PLA2 and SOD in CSVD 
patients with cognitive impairment. 
Lp-PLA2 is a recognized marker of systemic vascular 
and neuro inflammation and cerebral/cardiovascular risk, 
which has been related to ischemic stroke and vascular 
dementia [22, 23]. The differences of blood Lp-PLA2 
might be important, as plasma Lp-PLA2 levels change 
dynamically early after a cerebral-vascular event and 
reflect its action in the brain [24]. Several recent studies 
have examined Lp-PLA2 levels in the acute period after 
transient ischemic attack (TIA) or stroke and observed 
elevated levels of plasma Lp-PLA2, which were 
associated with early recurrent stroke [24, 25]. In this 
study, excluding other confounders (such as gender, age, 
years of education, BMI, hypertension, diabetes, CHD,  
medical statin use, total cholesterol, HDL-C, LDL-C, urea, 
Cr, UA and APOE), significantly lower levels of Lp-
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PLA2 in CVSD patients with MCI or SCI were observed 
compared to those in CVSD patients with NC (Fig. 2), and 
signifcant differences of Lp-LPA2 and SOD were noted 
among NC, MCI and SCI groups (Table 1). A significant 
correlation (Fig. 2C) between Lp-PLA2 and SOD was 
observed, suggesting that there might be a linkage 
between Lp-PLA2 and SOD in CSVD. These 
observations suggest that Lp-PLA2 might play important 
roles in preventing cognitive impairment development in 
CSVD. This result is consistent with previous findings  
that indicated antioxidative effects of Lp-PLA2 [26-28].   
Recent findings have indicated that WMHs are 
associated with the cognitive impairment in CSVD [4, 29-
31], and our results (Fig. 3D, E) are consistant with these 
findings. Furthermore, we note that the lower Lp-
PLA2/SOD levels in the severe WMH CSVD patients  
(Fazekas 3 group) were found compared to those in the 
mild white matter lesion group (Fazekas 1 group; Fig. 3), 
stronlgy implying that lower levels of Lp-PLA2/SOD 
may mediate cognitive impairment in CSVD patients, 
probably partially via white matter lesion and lacunes. 
Based on this finding, we ask whether LP-PLA2 and SOD 
are correlated to cognitive impairment, and whether their  
lower levels are independently associated factors in 
mediating cognitive impairment in CSVD patients. 
Some prior studies have suggested that the 
association between Lp-PLA2 and vascular events is  
strongest in patients with lower LDL-C levels [32] and 
have found a strong correlation between LDL-C and Lp-
PLA2 in recurrent vascular events [24]. In contrast, 
another study found no significant difference in the 
predictive value of Lp-PLA2 based on baseline LDL-C 
level [33]. In our study, there was evidence of variability 
in the strong correlation between Lp-PLA2 and cognitive 
impairment in CSVD patients, which was independent of 
circulating LDL-C levels (Fig. 4A, B; Table 2), directly 
indicating that circulating LDL-C levels in CSVD patients  
with cognitive impairment may not influence or 
participate in the disease pathogenesis but rather that 
circulating Lp-PLA2 may influence CSVD patients via 
regulating vascular and neuroinflammatory mechanisms 
but not lipid metabolism. 
The relationship between Lp-PLA2 and cognitive 
impairment reported in other studies has been inconsistent. 
Savas et al., indicated that Lp-PLA2 levels is higher in 
healthy subjects compared to AD patients, implying that 
Lp-PLA2 may play an anti-inflammatory or anti-
oxidative effects in AD [34]. A small cross-sectional 
study of 78 AD cases, 59 amnestic MCI cases, and 66 
cognitively normal controls performed by Davidson et al., 
did not find a significant association between Lp-PLA2 
and AD [35]. One prospective Rotterdam study and Texas 
Alzheimer’s Research and Care Consortium case-control 
study showed that the levels of Lp-PLA2 were associated 
with an increased risk of vascular dementia (VD) and AD,  
independent of other cardiovascular disease (CVD) and 
inflammatory factors [23, 36]. The discrepancy between 
our findings and other studies may be explained by 
differences in study design, different selected subjectes, 
data collection, and the number of variables used in the 
adjusted models to determine in these studies. In the 
current study, CSVD but not AD patients were chosen, 
and we only measured Lp-PLA2 mass. Lp-PLA2 mass 
detects a portion of the total Lp-PLA2, mainly the Lp-
PLA2 associated with HDL, which is the “good 
cholesterol” that displays protective effects [16]. In the 
current study, in the plasma we did not noted any 
differences of systemically infection-related 
inflammatory mediators (such as a leukocyte, hs-CRP, 
neutrophile granulocyte, ESR and uric acid; Table 1) 
between CSVD patients and healthy subjects. Adjust for 
those infective and inflammatory potential confounders, 
and due to the nature and changes in circulating Lp-PLA2 
in CSVD patients, our findings suggest that peripheral 
vascular or neuroinflammatory damage may be a key 
mediating mechanism by which Lp-PLA2 predisposes 
CSVD patients to cognitive impairment. 
In addition, we observed a similar trend upon 
examination of the levels of plasma SOD across CSVD 
groups (Fig. 4C, D), strongly suggesting that lower levels 
of SOD may be correlated to cognitive impairment, and 
the lower SOD level is independent risk factors in 
mediating cognitive impairment in CSVD patients. SOD 
levels in CSVD patients move in a similar direction as the 
levels of Lp-PLA2, further confirming that some anti-
inflammatory and proinflammatory-related markers may 
behave similarly in certain circumstances. SOD is 
recognized as an antioxidative stress and anti-
neuroinflammatory-related mediator [37-39]. The gradual 
downregulation of SOD levels in CSVD patients  
according to the severity of cognitive impairment and the 
significant positive correlation between SOD levels and 
the degree of cognitive impairment strongly suggest that 
more circulating oxidative stress and inflammatory 
markers may be present in CSVD subjects with cognitive 
impairment than in those with NC. These data suggest that 
plasma SOD levels are not increased in these patients with 
cognitive impairment; rather, the decline in SOD levels  
indicates a deficit in antioxidant defense mechanisms in 
those CSVD subjects with cognitive impairment, since 
these CSVD patients are unable to remove the circulating 
superoxide anion, therefore suffering an increase in small 
vascular damage induced by ROS and neuroinflammation.  
Thus, a lower level of plasma SOD is associated with 
increased vascular damage. Due to the retrospective 
nature of this study, we cannot exclude the possibility that 
CSVD patients with cognitive impairment produce less 
SOD and/or that CSVD patients with NC produce more 
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SOD. However, longitudinal studies may provide a clue 
as to whether Lp-PLA2 and SOD play crucial roles in the 
development of cognitive impairment in subjects with 
CSVD.                      
       Our results further indicate that only Lp-PLA2 and 
SOD but not hypertension, UA, Cr, HDL-C, or LDL-C are 
independent predictors of cognitive impairment in 
patients with CSVD (Table 2). This interesting finding 
demonstrates that Lp-PLA2 and SOD may directly 
participate in the pathogenesis of cognitive impairment in 
CSVD via regulating vascular and neuroinflammatory 
damage in circulating blood. Since both Lp-PLA2 and 
SOD are involved in the neuropathogenesis of CSVD 
patients and only some but not all CSVD subjects display 
cognitive impairment, we attempted to determine whether 
Lp-PLA2 and SOD have enough discriminative power to 
distinguish CSVD patients with cognitive impairment  
from those with NC. ROC curve analysis revealed an 
AUC of 0.737 for Lp-PLA2 and 0.670 for SOD, 
indicating that both had an acceptable sensitivity and 
specificity for the potential discrimination of CSVD 
patients with MCI from those with NC, and Lp-PLA2 had 
better discrimination accuracy than SOD. The ROC 
analysis strongly suggests that Lp-PLA2 and SOD can 
significantly discriminate CSVD patients with MCI from 
those with NC and therefore could be used as a valuable 
diagnostic tool in early screening for cognitive 
impairment in CSVD subjects. Moreover, the 
combination of Lp-PLA2 and SOD produced a larger 
AUC of 0.770 with a sensitivity of 80% and specificity of 
69.7% in the ROC analysis than Lp-PLA2 or SOD alone,  
strongly implying that the diagnostic accuracy of the 
combination of the two variables was superior to that of 
either variable alone in differentiating CSVD patients  
with different cognitive status.  
        The present study is limited mainly by its 
retrospective nature, assessing plasma levels of Lp-PLA2 
and SOD in a relatively small sample size of CSVD 
patients at a single time point. Prospective and 
longitudinal studies are needed, and randomized trials of 
potent reversible pharmacological Lp-PLA2 inhibitors or 
SOD agonists may help to clarify whether modification of 
Lp-PLA2 or SOD can delay the progression of CSVD. 
 A study strength is that there is very limited evidence 
that Lp-PLA2 and SOD, especially SOD, are significant 
and independent predictors associated with cognitive 
impairment in CSVD patients. The observed association 
of Lp-PLA2 and SOD with CSVD in our study is  
consistent with the hypothesis that Lp-PLA2 and SOD, as 
measured in peripheral blood, may reflect vascular and 
neuroinflammatory mechanisms. The relationship 
between Lp-PLA2/SOD and CSVD is highly likely to be 
mediated at least partially via vascular and 
neuroinflammatory mechanisms. These findings may be 
important for health care facilities that have limited access 
to Neurologists specialized in the diagnosis of CSVD with 
cognitive impairment. Further research in these areas is of 
great importance because Lp-PLA2 and SOD are 
modifiable risk factors and, if further confirmed, may be 
considered as therapeutic targets for preventing cognitive 
impairment development in CSVD and reducing its 
severity.  
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